Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel?s active metabolite
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12inhibitor, compared with clopidogrel in healthy humans
Prasugrel
